🔎 Trials Near Me

Home › Borderline Personality Disorder › NCT06446765

Mindfulness-based Neurofeedback to Augment Psychotherapy for Adults With Borderline Personality Disorder

RecruitingPhase 2

Mindfulness-based Neurofeedback to Augment Dialectical Behavior Therapy (DBT) for Adults With Borderline Personality Disorder (Aim 1)

Who can join

Ages 18 to 60 · All sexes

Full eligibility criteria
Inclusion criteria:

* age 18-60,
* be able to provide written informed consent,
* meet criteria for BPD on semi-structured clinical interview,
* able to plan to keep any prescribed medications and psychotherapy constant during the study
* fluent in English.

Exclusion criteria:

* current DBT psychotherapy outside the study
* lifetime primary psychotic disorder
* manic episode in the last one year
* developmental disorder (e.g. autism)
* history of learning disorder
* severe substance use disorder in the last 3 months
* active suicidal ideation with intent or plan in the past 3 months
* history of major medical or neurologic disorder
* MRI contraindications, including pregnancy
* poor performance on reading task (WRAT \> 11 errors)
* newly prescribed medications in the past 8 weeks
* daytime sedating medications (e.g. benzodiazepines, opiates, sedating neuroleptics)
* any scheduled daily benzodiazepines
* change in psychotherapy type or frequency in the past 12 weeks.
* At the discretion of the study PI

Eligibility will be determined by study personnel.

About the study

The purpose of this study is to test the ability of mindfulness-based real time functional magnetic resonance imaging (fMRI) neurofeedback (mbNF) to increase the benefits of evidence-based psychotherapy for adults with Borderline Personality Disorder (BPD).

What is being tested

Sponsor: Yale University · Participants: 150 · Started: Mar 13, 2025

Contact the study team

Official record on ClinicalTrials.gov — NCT06446765

Locations in the U.S.

ConnecticutConnecticut Mental Health Center, New Haven

Conditions

From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.